[New agents for solid tumours].
Raida
M
M
Universität Leipzig, Zentrum für Innere Medizin, Abt. Hämatologie und Onkologie und Klinik Bergisch-Land Wuppertal. raida@klinik-bergisch-land.de
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
C108123:4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011720:Pyrazoles; D011743:Pyrimidines; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases